El interés en corto de Deutsche Bank da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Deutsche Bank. Los datos de interés en corto se actualizan cada dos semanas.

Deutsche Bank (NYSE:DB) Bolsa, Informe de interés en corto

Deutsche Bank

Deutsche Bank is a universal bank operating on a global scale. The bank offers corporate, retail, investment banking, private banking, and asset management to its clients.

Equities

News

Legal

Movers

Media

Deutsche Bank logra avances en el litigio de Postbank, alcanzando acuerdos y mejorando sus perspectivas de ganancias.

¿Qué está pasando con las acciones del Deutsche Bank (DB) el viernes?

$BTC

$ETH

El Ibex 35 y otras importantes bolsas europeas se encuentran en estado de preparación para el inicio del Simposio de Jackson Hole y la publicación de las actas de la última reunión del Banco Central Europeo (BCE).

Ibex 35 y bolsas europeas en tensión antes de Jackson Hole y decisiones de Powell

Deutsche Bank AG

Invesco DB Agriculture Fund

Xtrackers MSCI All World ex US Hedged Equity ETF

INVSC DB AGRICULTURE ETF

Invesco DB Base Metals Fund

INVSC DB BASE METALS ETF

Invesco DB Commodity Index Tracking Fund

DeepBrain Chain

DECIBEL CANNABIS CO INC by Decibel Cannabis Co Inc.

Decibel Cannabis Co Inc

INVSC DB COMMODITY INDEX TRACKNG ETF

Diebold Nixdorf Incorporated Common stock

Diebold Nixdorf Inc

DOUBLEDRAGON CORP by DOUBLEDRAGON CORP.

Invesco DB Energy Fund

Xtrackers MSCI EAFE Hedged Equity ETF

Litman Gregory Funds Trust iMGP DBi Hedge Strategy ETF

Xtrackers MSCI Emerging Markets Hedged Equity ETF

Xtrackers MSCI Europe Hedged Equity ETF

Xtrackers MSCI Eurozone Hedged Equity ETF

INVSC DB ENERGY ETF

DUXTON BROADACRE FRMS LTD by DUXTON BROADACRE FARMS LTD.

Duxton Farms Ltd

PANEX RESOURCES INC by Panex Resources Inc.

Panex Resources Inc

Digital Brands Group, Inc. - Common Stock

Digital Brands Group Inc

DBX ETF Trust Xtrackers MSCI Germany Hedged Equity ETF

Designer Brands Inc. Class A Common Stock

Designer Brands Inc

Dacotah Banks Inc

Innovator ETFs Trust DOUBLE STACKER 9 BUFFER ETF JANUARY

Xtrackers MSCI Japan Hedged Equity ETF

Spetz Inc Ordinary Shares

Spetz Inc

DoubleLine Opportunistic Credit Fund Common Shares of Beneficial Interest

Doubleline Opportunistic Credit Fund

DOUBLEVIEW GOLD CORP by Doubleview Gold Corp.

Doubleview Gold Corp

FIBRA Macquarie Certificados Bursatiles Fiduciarios Inmobiliario Series -12-

FIBRA Macquarie

iMGP DBi Managed Futures Strategy ETF

DBM Global Inc

DIGITAL BRAND M & M GRP by Digital Brand Media & Marketing Group, Inc.

Digital Brand Media & Marketing Group Inc

Cibanco S A Institucion De Banca Multiple ertificados Bursatiles Fiduciarios Inmobiliaro Series -12-

Cibanco S A Institucion De Banca Multiple

DoubleLine ETF Trust DoubleLine Opportunistic Bond ETF

Invesco DB Oil Fund

DEUTSCHE BOERSE AG NAMEN by Deutsche Boerse AG

Deutsche Boerse AG

DEUTSCHE BOERSE UNSP/ADR by Deutsche Boerse AG

Diablo Resources Ltd

D BOX TECHS INC ORD A by D-Box Technologies, Inc.

D-Box Technologies Inc

INVSC DB OIL ETF

Invesco DB Precious Metals Fund

ISHARES BRIC 50 UCITS USD DIST ETF

DigitalBridge Group Inc

DigitalBridge Group, Inc. 7.125% Series H

DigitalBridge Group, Inc. 7.125% Series J

DAYBREAK OIL & GAS INC by Daybreak Oil & Gas, Inc.

Daybreak Oil & Gas Inc

Fibra Inn Certificados Bursatiles Fiduciarios Inmobiliario Series -13-

Fibra Inn

DBS GROUP HLDGS LTD ORD by DBS Group Holdings Ltd.

DBS Group Holdings Ltd

DBS GROUP HLDGS LTD S/ADR by DBS Group Holdings Ltd.

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

Dropbox Inc

XTRACKERS STX GLBL ETF 1D by Xtrackers

DEUTSCHE BANK N ORD

Banks across the globe have been continuously undertaking restructuring efforts to focus more on core operations. While these efforts are expected to result in elevated expenses, they will aid growth in the long run. While the uneven economic recovery in developed and emerging nations has been hurting revenue growth for companies within the Zacks <a href="https://www.zacks.com/stocks/industry-rank/stocks-in-industry/banks-foreign-12/stocks-in-industry">Foreign Banks</a> Industry, the current high interest rate environment will continue to provide support.
Thus, despite the geopolitical concerns, industry players like HSBC Holdings plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hsbc#NYSE">HSBC</a>), Barclays PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bcs#NYSE">BCS</a>) and Deutsche Bank Aktiengesellschaft (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/db#NYSE">DB</a>) are well-poised to gain from relatively high rates.
<h3>About The Industry</h3>
The Zacks Foreign Banks Industry consists of overseas banks with operations in the United States. Since a foreign banking organization may have federal and state-chartered offices in the country, the Federal Reserve plays a major role in supervising their U.S. operations. In addition to providing a broad range of products and services to customers in the United States, the banks offer financial services to corporate clients having businesses in the country. The financial firms establish relations with U.S. corporations operating in their home countries. Some units of foreign banks offer a broad range of wholesale and retail services, and conduct money-market transactions for their parent organizations. Some firms are involved in developing only specialized services.
<h3>3 Foreign Bank Industry Trends To Watch</h3>
High Interest Rate Environment to Aid Top-Line Growth: The efforts undertaken by the central banks across the globe to cushion economies from the pandemic-induced economic slowdown in 2020 (reducing benchmark interest rates to record lows) were successful in aiding immediate economic growth. However, it eroded banks&#39; profitability to a great extent. The pace of economic recovery, which has been uneven in the developed (home to a number of major foreign banks) and emerging nations, also hampered banking operations globally. Nevertheless, almost all central banks across the globe began raising interest rates from the beginning of 2022 to counter inflation, which supported banks&#39; top-line growth. While higher deposit costs might continue to weigh on banks&#39; net interest income and margin growth to some extent, banks are expected to keep getting support amid the current high interest rate environment. Despite the fact that central banks across the globe have started with rate cuts, interest rates are likely to remain relatively high in the near term. The efforts undertaken by most banks to diversify revenue sources to become less dependent on spread income will likely support non-interest income growth. 
Restructuring Efforts Likely to Keep Costs Elevated: Several foreign banks are undertaking business-restructuring efforts. Many banks have either been divesting or closing non-core operations to increase focus on core businesses and regions. While restructuring efforts are expected to boost growth in the long run, these have been leading to higher expenses. Increased costs related to technology upgrades are likely to keep hampering banks&#39; bottom-line growth to some extent in the near term. 
Uneven Global Economic Recovery Poses Concern: After the coronavirus outbreak, business confidence was shattered across the globe as the pandemic loomed over corporate earnings and economic growth. While the economy has recovered from the negative impacts of the pandemic, growth has slowed in some regions because of certain other geopolitical concerns. Banks&#39; performances are directly linked to the performance of the overall economy. Thus, uneven economic growth may hurt banks&#39; finances to an extent in the upcoming period.
<h3>Zacks Industry Rank Indicates Bright Prospects</h3>
The Zacks Foreign Banks Industry is a 66-stock group within the broader Zacks <a href="https://www.zacks.com/stocks/industry-rank/sector/Finance-13">Finance</a> Sector. The industry currently carries a Zacks <a href="https://www.zacks.com/stocks/industry-rank/industries/">Industry Rank</a> #49, which places it in the top 20% of more than 250 Zacks industries. 
The group&#39;s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates outperformance in the near term. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1. 
The industry&#39;s positioning in the top 50% of the Zacks-ranked industries is a result of an impressive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gaining confidence in this group&#39;s growth potential. The industry&#39;s most recent earnings estimates for 2024 have been revised 2.9% higher since the end of June 2024. 
Thus, we present a few stocks from the industry that you may want to keep an eye on. But before that, let us check out the industry&#39;s recent stock market performance and valuation picture.
<h3>Industry Underperforms S&amp;P 500 But Outperforms Finance Sector</h3>
The Zacks Foreign Banks Industry has underperformed the S&amp;P 500 but outperformed its sector in the past two years. 
Stocks in the industry have collectively gained 52.5%. The S&amp;P 500 composite has rallied 56.5% and the Zacks Finance Sector has appreciated 47.2%.
<h3>Two-Year Price Performance</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/io1(17).jpg" style="height:341px; width:620px" />
<h3>Industry&#39;s Current Valuation</h3>
One might get a good sense of the industry&#39;s relative valuation by looking at its price-to-tangible book ratio (P/TBV), which is commonly used for valuing banks because of large variations in their earnings results from one quarter to the next. 
The industry currently has a trailing 12-month P/TBV of 2.31X. This compares with the highest level of 2.34X, the lowest level of 0.79X and the median of 1.62X over the past five years. Additionally, the industry is trading at a significant discount compared with the market at large, as the trailing 12-month P/TB for the S&amp;P 500 composite is 14.90X, which the chart below shows.
<h3>Price-to-Tangible Book Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/io2(16).jpg" style="height:344px; width:620px" />
As finance stocks typically have a lower P/TBV ratio, comparing foreign banks with the S&amp;P 500 might not make sense to many investors. However, a comparison of the group&#39;s P/TBV ratio with that of its broader sector ensures that it is trading at a decent discount. The Zacks Finance Sector&#39;s trailing 12-month P/TBV of 5.69X and the median level of 4.44X for the same period are above the Zacks Foreign Banks Industry&#39;s ratios.
<h3>Price-to-Tangible Book Ratio</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/io3(16).jpg" style="height:339px; width:620px" />
<h3>3 Foreign Banks Worth A&nbsp;Look</h3>
HSBC: Headquartered in London, it is a major global banking and financial services firm with $2.98 trillion in assets as of June 30, 2024. 
The company has been committed to bolstering its performance with a special focus on building operations across Asia. It intends to position itself as a top bank for high-net-worth and ultra-high-net-worth clients in the region. 
In sync with this, the company acquired Citigroup&#39;s retail wealth management business in China in June 2024, whereas it acquired Singapore-based SilkRoad Property Partners Group in January. HSBC re-launched its private banking business in India as the country has been experiencing a surge in the number of super-rich. 
In 2022, HSBC acquired 100% of the issued share capital of AXA Insurance in Singapore and L&amp;T Investment Management Limited. These initiatives will likely help the company strengthen its position in the region, which constitutes more than half of its operations. 
HSBC has been restructuring its operations to further improve operating efficiency. In 2020, it announced the transformation plan to reshape underperforming businesses, simplify complex organizations and reduce costs. The company realized gross savings of $5.6 billion, with cost to achieve a spend of $6.5 billion by 2022-end. HSBC expects to achieve additional cost savings this year, driven by the actions undertaken in 2023. 
In April 2024, the company announced an agreement to divest its Argentina business, whereas in February, HSBC agreed to sell its Armenian unit. The company has already exited retail banking businesses in the United States, Canada, France, New Zealand, Greece and Russia. 
HSBC&#39;s brand, capital strength, extensive global network and positioning enable it to continuously attract and retain clients. The company&#39;s product and service leadership in alternative investments, foreign exchange, credit, investment advice and many other cross-border banking services help it widen its customer base. 
Shares of the company have gained 16.9% on the NYSE in the past year. The Zacks Consensus Estimate for its current-year earnings has moved 2.7% higher in the past 60 days. Currently, HSBC carries a Zacks Rank #2 (Buy). 
You can see <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link_invideas&amp;ICID=zpi_1link_invideas">the complete list of today&#39;s Zacks #1 Rank (Strong Buy) stocks here</a>.
<h3>Price And Consensus: HSBC</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/io4(15).jpg" style="height:350px; width:620px" />

Barclays: Headquartered in London, this Zacks Ranked #3 (Hold) company is a major global banking and financial services firm with &pound;1,576.6 billion ($1,993.5 billion) in total assets as of June 30, 2024. 
Over the past few years, Barclays has been striving to simplify operations and focus on core businesses. As part of its business overhaul, the company announced changes to its operating divisions effective first-quarter 2024. 
In July 2024, the company announced the divestiture of its German consumer finance business, while it announced the disposal of its Italian mortgage portfolio (which was completed in the second quarter of 2024) in April. Additionally, the company has sold $1.1 billion in credit card receivables to Blackstone&#39;s Credit &amp; Insurance segment to bolster lending capacity for Barclays Bank Delaware in the United States. 
This February, the company announced a deal to acquire Tesco&#39;s retail banking business. The move is expected to complement its existing business and strengthen its position in the market. In 2023, Barclays acquired Kensington Mortgage, which bolstered its mortgage business in the U.K. Driven by these initiatives, the company&#39;s profitability is expected to improve over time. 
Moreover, Barclays&#39; initiatives to improve efficiency over the past few years have been bearing fruit, as evident from a fall in expenses. While total operating expenses increased in 2022, 2023 and the first half of 2024, the metric declined, seeing a compound annual growth rate (CAGR) of 2.4% over the six years ended 2021. As BCS&#39; business-restructuring initiatives continue to offer support, overall costs are expected to be manageable. 
Driven by the structural cost actions taken in 2023 and ongoing efficiency investments, expense savings of &pound;1 billion are anticipated in 2024, with a payback of less than two years. By 2026, management expects total gross efficiency savings of &pound;2 billion and the cost-to-income ratio in the high 50s. 
BCS shares have gained 62.1% on the NYSE in the past 12 months. The Zacks Consensus Estimate for the company&#39;s 2024 earnings has moved 1.2% higher in the past 60 days.
<h3>Price And Consensus: BCS</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/io5(17).jpg" style="height:350px; width:620px" /> 
Deutsche Bank: Headquartered in Frankfurt am Main, this is the largest bank in Germany and one of the largest financial institutions in the world, as measured by total assets. It offers a wide variety of investment, financial and related products and services. 
Growth in net revenues has been a key strength at Deutsche Bank. The metric has seen a CAGR of 2.7% over the five years ended 2023, with the uptrend persisting in the first six months of 2024. Notably, the bank&#39;s efforts to shift focus from investment banking to more stable businesses, such as private bank, corporate bank and the asset management unit, will likely continue to aid revenues in the upcoming period. 
The bank closed the acquisition of Numis, which is likely to aid the Asset Management segment. Management expects revenues to witness a CAGR of 5.5-6.5% for the period between 2021 and 2025. 
Moreover, solid deposit balances support DB&#39;s financials. The metric witnessed a CAGR of 2% over the five years ended 2023, with the uptrend continuing in the first half of 2024. The company benefits from its well-diversified deposit base across various client segments and regions. Also, its loan-to-deposit ratio reflects a strong and stable funding base. Thus, we believe that the stable deposit balance will strengthen the company&#39;s balance sheet. 
Deutsche Bank has been returning excess capital to shareholders through dividends and share buybacks. At its annual general meeting in May 2024, the bank proposed 2023 dividends of 45 cents per share, aggregating approximately &euro;900 million. This indicates an increase from 30 cents per share paid out in 2022. For 2024 and 2025, the company plans to pay out dividends of 68 cents and &euro;1 per share, respectively. 
The company also has a share repurchase program. In July 2024, the bank completed the share repurchase program launched on March 4, 2024. Under this program, 46.4 million shares were repurchased for &euro; 675 million, bringing cumulative shareholder distributions through dividends and share repurchases to &euro; 3.3 billion since 2022. DB is committed to capital distributions of &euro;8 billion over the financial years 2022-2026. 
The Zacks Consensus Estimate for the company&#39;s 2024 earnings has been revised 3.5% higher over the past 60 days. DB shares have gained 63.3% on the NYSE in the past year. The company currently carries a Zacks Rank of 3.
<h3>Price And Consensus: DB</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/io6(15).jpg" style="height:351px; width:620px" />
<a href="https://www.zacks.com/commentary/2343164/3-stocks-to-consider-from-the-prospering-foreign-banks-industry?cid=CS-BENZ-FT-industry_outlook-2343164">To read this article on Zacks.com click here.</a>

Markets

Trading Ideas

General

HSBC

3 Stocks To Consider From The Prospering Foreign Banks Industry

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 20:
Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>): The gold-mining company saw increased interest from readers this week on the heels of a 50 basis point cut to interest rates by the Federal Reserve, which saw gold prices rise. The interest also comes after Barrick Gold CEO Mark Bristow spoke at the Gold Forum Americas earlier this week and<a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation"> said the company expects </a>30% growth in gold-equivalent ounces by the end of the decade from its existing assets. 
Bristow's comments emphasized the company's current mines and those in development, as the industry experiences a surge in merger and acquisition activity. The CEO also highlighted how the company is expanding its copper portfolio, which could be something exciting to watch for investors.
Barrick shares were down 2% over the last five trading days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below. The stock is up 14% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png" alt="" class="wp-image-558808" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-768x371.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>): The biopharmaceutical company <a href="https://www.benzinga.com/news/24/09/40941193/galmed-pharmaceuticals-stock-is-soaring-thursday-heres-why">saw shares soar </a>during the week after an announcement on drug development activities. Galmed plans to add drug developments that target cardiac fibrosis and colorectal and hepatic cancers. The company will release data from the studies during the fourth quarter.
"The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers," Galmed CEO Allen Baharaff said.
Large interest in Galmed saw shares halted several times during the trading week. Helping with volatility in the biopharmaceutical company is the low-float of the stock with around 625,000 shares available according to Benzinga Pro. Low-float stocks can often see high volatility on company announcements.
The stock was up 160% over the last five days and up nearly 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png" alt="" class="wp-image-558810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Read Also:&nbsp;<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>): The software company is seeing a large increase in interest from readers ahead of its third-quarter financial results. Analysts expect the company to report revenue of $2.74 billion, up from $2.29 billion in last year's third quarter.
The company has beaten analyst revenue estimates in six straight quarters. Analysts expect the company to report earnings per share of $3.46, up from $2.92 in last year's third quarter. ServiceNow has beaten earnings estimates from analysts in more than 20 straight quarters.
The company's earnings report will show investors and analysts whether revenue growth and AI platform demand are continuing to strengthen. The company saw subscription revenue up 23% year-over-year in <a href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every">the second quarter </a>and said it was helping meet demand from CEOs looking for new growth as ServiceNow reinvents "every workflow, in every company, in every industry with GenAI at the core."
ServiceNow shares are up 4% over the last five days and up 34% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png" alt="" class="wp-image-558811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-768x396.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>): It's not every week that a bank stock makes its way on the Stock Whisper Index, but here we are. Deutsche Bank saw strong interest from readers, which could be due to bank stocks getting a lift after the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">interest rate cut was announced.</a> 
The move could see lenders have their balance sheets strengthened going forward and see increased demand for loan activity. Deutsche Bank reports third-quarter financial results in October and could comment on demand and what the future looks like for the company and the sector.
Shares were up 5% over the last five days and 24% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png" alt="" class="wp-image-558812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): The medical equipment company saw strong interest from readers during the week, which comes on the heels of acquisition announcements, new products <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">and analyst notes</a>. 
The company recently unveiled new foot and ankle solutions that can help restore limb length. Stryker closed its acquisition of privately held care.ai, a company helping with AI-assisted virtual care workflows and smart room technology. The company said the acquisition will help accelerate its digital vision and could expand its healthcare IT business. 
On Friday, Stryker closed its acquisition of NICO Corporation, a company with a surgery method for tumor and intracerebral hemorrhage procedures. Stryker also announced an acquisition of pain management company Vertos Medical in August. Together, the acquisitions and new products could have investors excited about the company's future and its potential diversification efforts.
Piper Sandler recently maintained an Overweight rating and a $380 price target on the stock. Wolfe Research initiated coverage with an Outperform rating and a $405 price target.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png" alt="" class="wp-image-558813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-768x387.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 30</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 6</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">September 13 </a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40838414/gold-miners-eye-best-1-day-rally-in-6-months-as-gold-hits-fresh-record-highs-todays-environment-">Gold Miners Eye Best 1-Day Rally In 6 Months As Gold Hits Fresh Record Highs: &#8216;Today&#8217;s Environment Closely Resembles The 1970s&#8217;</a></li>
</ul>
Photo: Benzinga

Exclusives

GLMD

GOLD

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

WIIM

CACC

CFBK

CRBG

FSFG

HBAN

NYCB

VBFC

Shares of bank stocks are trading lower in possible sympathy with Ally, which fell after the company's CFO noted credit challenges among borrowers. The sector earlier reacted to Fed Vice Chair for Supervision Barr previewing Basel and GSIB surcharge re-proposals.

Shares of bank stocks are trading lower after Fed Vice Chair for Supervision Barr unveiled Basel and GSIB surcharge re-proposals.

The latest equity research report from Pablo Zuanic of Zuanic &amp; Associates highlights key trends in Canada's cannabis market, noting a deceleration in recreational sales growth.
Data from StatCan reveals that sales for 2Q24 were down 4% year-over-year (YoY), contributing to a 1.3% decline year-to-date (YTD) compared to 14% growth in 1H23. In contrast, Hifyre data shows a 6% YTD growth through August.
If annualized, this growth would project a total<a href="https://www.benzinga.com/topic/canada-cannabis"> recreational market</a> size of C$5.47 billion for calendar year 2024, translating to US$102 per capita.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Market Share Shifts Among Top Players</h3>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>highlights notable shifts in market share among the top licensed producers (LPs). Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), once a dominant player, saw its share drop by 1.5 percentage points to 9.6% in August, continuing its decline over recent quarters. Decibel (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) also experienced a decline, dropping 0.9 percentage points to 5.2%.
Meanwhile, Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) experienced strong growth, increasing its market share to 7.9%, up from 6.1% a year ago, representing a 34% year-over-year growth. Similarly, Cronos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) and Organigram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) posted gains, with Cronos maintaining a steady 5.3% share (up 24% YoY), and Organigram growing its market share to 7.2%, up from 6.6% a year ago, reflecting 15% (YoY) growth.
Additionally, Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) and Cannara Biotech (unlisted) gained 0.5 points each, reaching 5.2% and 3.4% market shares, respectively.
Here is a breakdown of the major players:
<ul>
<li>Village Farms: sales grew +34% YoY, holding a 7.9% market share in August (up from 6.1% a year ago).</li>
<li>Cronos: +24% YoY growth in sales, maintaining a 5.3% share, consistent with previous quarters.</li>
<li>Organigram: +15% YoY growth in sales, with a market share of 7.2% in August, up from 6.6% a year ago.</li>
<li>Tilray: -20% YoY decline in sales, with a 9.6% market share in August, down from 10.1% earlier in the quarter.</li>
<li>Decibel: -25% YoY decline in sales, holding a 5.3% market share, down from 7.4% a year ago.</li>
</ul>
<h3 class="wp-block-heading">Format Preferences Continue To Evolve</h3>
The Canadian cannabis market is shifting towards newer product formats, with some segments outperforming others. Flower remains the largest category, accounting for 36% of sales in June-August 2024, down from 41% in 1Q23 and 57% in 1Q21. This decline reflects changing consumer preferences, as <a href="https://www.benzinga.com/markets/cannabis/24/06/39508155/900-pre-rolls-per-hour-upgrade-from-manual-to-automatic-speeds-up-joint-production-enhances-marg">pre-rolls</a> and vapes gain market share.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">Pre-rolls</a> now represent 34% of total sales, up from 27% in 1Q23 and 17% in 1Q21. The segment grew 11% year-over-year (YoY) in the June-August period, driven by consumer demand for convenience. Decibel leads with a 10.4% share, though it fell to 9.7% in August. Tilray holds 8.3%, and Organigram has 6.4%.
<a href="https://www.benzinga.com/general/biotech/24/08/40341814/tony-starks-choice-vape-synergy-innovations-strategic-move-to-restore-brands-identity-lead-market">Vapes </a>account for 16% of sales, up from 15% in 1Q22 and 14% in 1Q21, supported by 8% yoy growth. Motif Labs leads with 20.6%, followed by Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) at 12.4%, up from 10.7% in 2Q24.
Other formats, like concentrates, edibles, beverages, and oils, hold smaller shares. Concentrates and edibles each represent 5%, while <a href="https://www.benzinga.com/topic/cannabis-beverages">beverages </a>and oils account for 2% each. Concentrates grew 5% YoY, while edibles declined by 5%. Beverages saw a 6% YoY increase, indicating gradual consumer adoption.
Read Next: S<a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">NDL Wins Bid For Indiva, Secures Major Deal To Boost Cannabis Edibles Market Share In Canada</a>

Analyst Color

Cannabis

Market Summary

Retail Sales

Analyst Ratings

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRON

TLRY

TSXV:DB

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

Barclays analyst Flora Bocahut upgrades Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) from Equal-Weight to Overweight.

Upgrades

Barclays Upgrades Deutsche Bank to Overweight

Deutsche Bank AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) shares are trading higher today. The company <a href="https://www.db.com/news/detail/20240821-deutsche-bank-reaches-settlements-with-a-large-share-of-the-plaintiffs-in-postbank-takeover-litigation-matter-media-release?language_id=1">stated</a> that it has made substantial progress in its discussions with plaintiffs regarding the litigation over the Postbank takeover and the offer price paid to former Postbank shareholders.
On Thursday, the company reached agreements with over 80 plaintiffs, covering nearly 60% of the total claims.
The settlements are based on an offer of €31 per share, as proposed by the bank, and include a settlement with the largest individual plaintiff, who represents around one-third of all claims.
Elliott Investment Management is receiving nearly €200 million ($222 million) from Deutsche Bank to resolve the long-running legal dispute, Bloomberg <a href="https://news.bloomberglaw.com/mergers-and-acquisitions/elliott-gets-200-million-payday-from-deutsche-bank-settlement" target="_blank" rel="noreferrer noopener">reported</a>, citing people with knowledge of the matter. The report mentioned that the activist hedge fund was the largest plaintiff in the litigation over the Postbank takeover.
Deutsche Bank expects the settlement agreements reached so far to utilize around 45% of the total provisions set aside for the claims covered by these agreements.
The remaining provisions related to these plaintiffs will be released, which will have a positive impact of about €430 million on the bank&#8217;s pre-tax profit in the third quarter.
If Deutsche Bank reaches settlement agreements with additional plaintiffs, it could lead to further positive impacts on the total provisions set aside for the litigation.
In July, the bank reported first-half <a target="_blank" href="https://www.db.com/news/detail/20240724-deutsche-bank-reports-on-the-second-quarter-of-2024?language_id=1" rel="noreferrer noopener">2024</a> net revenue growth of 2% to €15.4 billion, with profit before tax at €2.4 billion-€3.8 billion excluding the Postbank litigation provision compared to €3.3 billion in the first half of 2023.
Price Action: DB shares are up 0.96% at $16.36 at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/40523059" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s Twitter-Clone Threads Explores Ad Integration, But Company Says &#8216;There Is No Immediate Timeline For Monetization&#8217; Yet</a></li>
</ul>

What's Going On With Deutsche Bank Stock Friday?

Deutsche Bank (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/db#NYSE">DB</a>) has achieved notable progress in talks with claimants involved in the legal dispute regarding its takeover of Postbank and the compensation paid to former Postbank shareholders.&nbsp;
The bank has reached settlement agreements with more than 80 claimants, who collectively make up nearly 60% of all claims in this lawsuit. These agreements are settled upon the bank&#39;s suggested price of &euro;31 ($34.5) per share. Among the claimants who agreed to a settlement also represented about one-third of all claims.
In April 2024, Deutsche Bank said that it could face claims up to &euro;1.3 billion ($1.4 billion) in a legal battle with former Postbank shareholders about its 2010 takeover. The former Postbank shareholders argued that a higher price should have been offered.
Deutsche Bank anticipates that the settlement agreements reached so far will burn approximately 45% of the total provisions taken for the claims of plaintiffs covered by the agreements. The remaining provisions linked to these specific plaintiffs will be released. It is expected that this action will positively affect the bank&#39;s tax profit for the third quarter by nearly &euro;430 million ($478.6 million). If Deutsche Bank enters into settlement agreements with additional claimants, this could have a positive impact on the overall litigation provisions.
In sync with this news, on Apr 26, 2024, the Higher Regional Court of Cologne looked into claims from former Postbank shareholders. The court hinted that it might back some of these claims in a future decision. Deutsche Bank didn&#39;t agree with the court&#39;s view. Still, it noted that the court&#39;s comments could influence an estimation of future financial outflows. The provision of &euro;1.3 billion for litigation related to the Postbank takeover resulted in a loss in the second quarter of 2024.
Over the past six months, shares of DB have gained 17.1% on the NYSE compared with the industry&#39;s growth of 13.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b4/75073.jpg?v=638750238" />
Image Source: Zacks Investment Research
Currently, Deutsche Bank carries a Zacks Rank #2 (Buy).
Due to the nature of its business, Deutsche Bank is involved in litigation, arbitration and regulatory proceedings in Germany and several jurisdictions outside Germany. The bank carried significant legal settlement costs in the past, which adversely impacted its financials. The recent litigation related to the acquisition of Postbank is likely to keep the expense fairly high. As a result, higher legal expenses are expected to continue putting pressure on DB&#39;s financials in the near term.
<h2>Legal Issues Faced by Other Finance Companies</h2>
In the first half of August, Piper Sandler Companies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pipr#NYSE">PIPR</a>) announced that it has agreed to pay a total civil penalty of $16 million to U.S. regulators for record-keeping failures. To settle investigations into its record-keeping practices, PIPR will pay $14 million to the Securities and Exchange Commission (&quot;SEC&quot;) and $2 million to the Commodity Futures Trading Commission (&quot;CFTC&quot;).
At the same time, Wells Fargo (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wfc#NYSE">WFC</a>) was also fined for its record-keeping lapses. The crackdown, led by the SEC and the CFTC, underlined the significance of keeping accurate records of employee communications in the financial industry. WFC had incurred the highest penalty among the firms targeted, amounting to $200 million.
<a href="https://www.zacks.com/stock/news/2325930/deutsche-bank-db-settles-60-of-claims-related-to-postbank-takeover?cid=CS-BENZ-FT-analyst_blog|company_news_finance_sector-2325930">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

PIPR

Deutsche Bank Settles 60% of Claims Related to Postbank Takeover

Deutsche Bank shares are trading higher after the company announced a $222 million settlement from a legal dispute with Elliott Investment Management.

<a href="https://news.bloomberglaw.com/mergers-and-acquisitions/elliott-gets-200-million-payday-from-deutsche-bank-settlement">https://news.bloomberglaw.com/mergers-and-acquisitions/elliott-gets-200-million-payday-from-deutsche-bank-settlement</a>
<ul>
<li>Dispute with Postbank investors goes back more than a decade</li>
<li>News comes as billionaire Elliott founder Paul Singer turns 80</li>
</ul>
Elliott Investment Management is receiving nearly €200 million ($222 million) from Deutsche Bank AG as the German lender moves to resolve a long-running legal dispute, people with knowledge of the matter said.
The activist hedge fund was the largest plaintiff in the litigation against Deutsche Bank over its Postbank takeover, which took place more than a decade ago, according to the people. It's now set for a payday after settling with the German lender, the people said, asking not to be identified because the information is private.
Deutsche Bank said late Wednesday it reached settlements with plaintiffs representing almost 60% …

'Elliott Gets €200 Million Payday From Deutsche Bank Settlement' - Bloomberg Law

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) reported on Wednesday its unaudited interim financial results for the second quarter ending June 30, 2024.
&#8220;Decibel has shown good discipline in reducing our current liabilities by ~5mm this quarter," said Benjamin Sze, Decibel&#8217;s CEO. "Market share has been challenged but early indications from Qwest relaunch suggest we will regain market share in flower.  A continued focus on execution and capital efficiency will serve as the platform for future growth.&#8221;
The company reported net revenue of CA$22.1 million ($16.1 million), down from CA$28.5 million in the prior year's period, representing a 22% year-over-year drop. Its first quarter report published this past April revealed a 16% year-over-year revenue drop to <a href="https://www.benzinga.com/markets/cannabis/24/05/39065170/decibel-cannabis-reports-16-yoy-drop-in-q1-revenue-ceo-expects-improved-q2-and-continued-path-to">CA$21 million and an adjusted net loss of CA$3.5 million.</a>
In his recent analysis senior analyst Pablo Zuanic of Zuanic &amp; Associates said Decibel&#8217;s management acknowledges the competitive pressures in the vape and pre-roll categories, particularly from competitors like Jeeter and Organigram.
"The company was slow to react to the rise of larger 510 cartridge formats and higher potency extracts," as highlighted in a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39146622/cannabis-slowdown-in-canada-analyst-spotlights-what-still-sells-and-where-the-money">recent recap</a> of Zuanic's analysis by Beniznga's <a href="https://www.benzinga.com/author/nicol-s-jose-rodriguez">Nicolás Jose Rodriguez.</a> "However, Zuanic shared new product launches in 2Q24 aim to address these gaps. Decibel is expanding distribution for infused pre-rolls and innovating around the Vox brand. Additionally, flower production at the company&#8217;s craft facilities is set to ramp up."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38492649/this-undervalued-cannabis-stock-has-another-year-of-growth-reports-record-2023-revenue-and-adjus">This Undervalued Cannabis Stock Has Another Year Of Growth: Reports Record 2023 Revenue And Adjusted EBITDA</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/14101101/CCC-Oct-24-Banner-1-47.gif" alt="" class="wp-image-494887" /></a></figure>
<h3 class="wp-block-heading">Q2 2024 Financial Highlights</h3>
<ul>
<li>Gross profit before fair value adjustments was CA$9.3 million, down from CA$12.3 million in the prior year's period.</li>
<li>Gross margin before fair value adjustments was 42% in the second quarter of 2024, compared to 43% in the second quarter of 2023.</li>
<li>Adjusted EBITDA came in positive at CA$3.9 million, down from CA$7.3 million adjusted EBITDA gain in the prior year's quarter.</li>
<li>Net income and comprehensive income was CA$122 000, compared to a net loss and comprehensive loss of CA$423 000 in the second quarter of fiscal 2023.</li>
<li>Cash flow from operations was CA$985 000, compared to CA$768 000 in the prior year's period.</li>
<li>Free cash flow was CA$895 000, up from CA$304 000 in the prior year's period.</li>
</ul>
<h3 class="wp-block-heading">Read Next:</h3>
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36291660/undervalued-cannabis-stock-this-company-could-reach-a-c-1b-valuation-on-the-back-of">Undervalued Cannabis Stock? This Company Could Reach A C$1B Valuation On The Back Of Pre-Roll Sales</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 4.29% higher at $0.0365 per share at the time of writing on Wednesday.

Earnings

DBCCF

Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches

ACRE

ALLY

ARES

ATCH

COHN

FUTU

HIPO

HOOD

HTGC

IBKR

JFIN

Janus Henderson Group plc Ordinary Shares

KSPI

LPLA

MOGO

MORN

NCPL

NDAQ

NRDS

NTRS

PRAA

RILY

SHF Holdings, Inc. - Class A Common Stock

SHFS

SNEX

SPGI

STEP

TBBK

TROW

VCTR

VOYA

Shares of companies within the broader financial sector are trading lower amid overall weakness following concerns about recently issued US economic data.

Brighthouse Financial, Inc. - Common Stock

ENVA

OSCR

SLQT

SOFI

UPST

VALU

Shares of companies within the broader financial sector are trading lower amid overall market weakness following weak US jobs data.

Shares of General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) fell sharply during Wednesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39934099/general-dynamics-hits-high-revenue-but-faces-earnings-hiccup-in-q2-details">second-quarter EPS results</a>.
Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
General Dynamics shares declined 5.2% to $279.26 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NuZee, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) jumped 192% to $3.01.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 142.4% to $3.0799 after falling over 22% on Tuesday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) surged 134% to $0.0609.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) gained 86% to $2.3300.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) gained 74.5% to $10.82.</li>
<li>Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) jumped 73.4% to $13.77 after the company announced that the company entered into a definitive merger agreement with Palvella Therapeutics.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 50% to $0.60 after licensing partner Pfizer&#8217;s Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec met its primary endpoint.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) gained 28% to $3.2212.</li>
<li>KORE Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NASDAQ">KORE</a>) gained 21.8% to $2.84.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) rose 20.5% to $6.87 after reporting unaudited 2024 second quarter and first half financial results.</li>
<li>PROG Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRG#NYSE">PRG</a>) climbed 20.4% to $41.71 after the company reported better-than-expected second-quarter financial results. Also, the company raised its FY24 guidance above estimates.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 19.4% to $94.69. The company on Monday announced a private placement financing.</li>
<li>Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) rose 18.4% to $3.71. Silynxcom received $815,000 in orders from Israel Defense Forces since July 2024.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 16.4% to $1.0009 after the company announced steady progress in its due diligence efforts in its proposed reverse merger with COVIRIX Medical and anticipates completion by the end of August 2024.</li>
<li>Flex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) gained 10.9% to $32.96 after the company reported better-than-expected second-quarter financial results.</li>
<li>Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) climbed 10.5% to $249.78 after the company reported better-than-expected second-quarter financial results.</li>
<li>Group 1 Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) gained 9.6% to $333.95 after the company reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) rose 9.2% to $113.18 after the company reported second-quarter financial results.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) gained 8.7% to $0.1809. Allarity Therapeutics revealed on Monday it received a "Wells Notice" from the U.S. Securities and Exchange Commission (SEC).</li>
<li>Mattel, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) gained 7.9% to $18.61 after the company reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) shares surged 7.5% to $113.33 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) gained 7% to $26.69 after the company reported better-than-expected <a>second-quarter </a>financial results.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) gained 6.8% to $148.17 after the company reported better-than-expected second-quarter financial results and the company and raised its FY24 guidance above estimates. Also, the company announced it authorized a $1.5 billion share buyback.</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) gained 3.1% to $18.78 following second-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares dipped 74.4% to $1.27. Azitra announced the pricing of $10.0 million public offering.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 58% to $2.42.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) dipped 43.8% to $4.25.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) fell 37.2% to $2.6199 after the company announced the pricing of a $2 million public offering of 469,340 common shares at $4.24 a share.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) dipped 34.2% to $0.1414.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) declined 26.9% to $57.46 after the company reported worse-than-expected quarterly financial results. Also, the company issued its FY25 EPS guidance below estimates.</li>
<li>Conn&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>) shares fell 26.7% to $0.3717 as the company announced plans to close 71 locations across 13 states.</li>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) fell 24.5% to $0.0868 after the company announced bankruptcy filing and voluntary delisting and SEC deregistration.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) declined 24.2% to $0.7350 after the company issued an update on Black Lake Uranium Project.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) shares declined 23.8% to $0.4228 after gaining 11% on Tuesday.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares fell 22.7% to $2.7750 after the company reported pricing of $55.0 million public offering of common stock, warrants and pre-funded warrants.</li>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) dipped 17.8% to $10.75 after the Phase 2 KINETIC 2 study of SAGE-324 did not demonstrate a statistically significant dose-response relationship on the primary endpoint.</li>
<li>Hawaiian Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HA#NASDAQ">HA</a>) dipped 13% to $11.33.</li>
<li>SFL Corporation Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFL#NYSE">SFL</a>) shares fell 12.3% to $12.23 after the company announced an offering of 8 million common shares.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares fell 12% to $216.78. Tesla reported weaker-than-expected earnings for its second quarter, while sales topped estimates. The company reported second-quarter deliveries of 443,956 vehicles and production of 410,831 vehicles, down 5% and 14% year-over-year, respectively.</li>
<li>Karooooo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) dipped 11.3% to $31.90 as the company announced the launch of secondary public offering of ordinary shares.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 10.2% to $15.29.</li>
<li>Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) dipped 9.5% to $14.41.</li>
<li>Chijet Motor Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) fell 9.3% to $4.61 after jumping 55% on Tuesday.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) dipped 9.1% to $25.14 after the company announced a primary offering of 25 million shares.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares declined 8.8% to $4.2150 after the company announced the departure of CCO Anil Kapur.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) fell 8.4% to $92.45.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) fell 8.2% to $56.97.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) shares fell 8% to $15.69 following second-quarter earnings.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) declined 8% to $14.25.</li>
<li>Weatherford International plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) dipped 7.6% to $123.57 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Roper Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NYSE">ROP</a>) fell 7.4% to $532.08 after the company reported worse-than-expected second-quarter sales results and issued third-quarter adjusted EPS guidance below estimates.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) shares fell 7.1% to $0.5479 after gaining around 23% on Tuesday.</li>
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) fell 6.9% to $71.36 after the company reported worse-than-expected second-quarter sales results and issued FY24 sales guidance below estimates.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) fell 5.5% to $367.84 after Piper Sandler downgraded the stock from an Overweight to Neutral and lowered its price target from $494 to $404.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) shares declined 4.1% to $174.29. Alphabet reported upbeat earnings and sales results for its second quarter on Tuesday. The company also announced a cash dividend of 20 cents per share to be paid on Sept.16 to shareholders of record as of Sept. 9.</li>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares fell 3.8% to $254.72 following third-quarter results.</li>
</ul>
Now Read This:  
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39932485/jim-cramer-calls-axsome-a-double-or-nothing-stock-says-sap-is-incredible">Cramer Calls Axsome A &#8216;Double Or Nothing Stock,&#8217; Says SAP Is &#8216;Incredible</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39932485/jim-cramer-calls-axsome-a-double-or-nothing-stock-says-sap-is-incredible">&#8216;</a></li>
</ul>

Comments

Deutsche Bank

Interés en corto

Deutsche Bank (NYSE:DB) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL